

# 1 **Discordance between gut-derived appetite hormones and** 2 **energy intake in humans**

3 Aaron Hengist<sup>1</sup>, Christina M. Sciarrillo<sup>1</sup>, Juen Guo<sup>1</sup>, Mary Walter<sup>1</sup>, Kevin D. Hall<sup>1\*</sup>

4 <sup>1</sup>National Institute of Diabetes and Digestive and Kidney Diseases, NIH, Bethesda MD, 20892,  
5 USA

6 \*Correspondence: [kevin.hall@nih.gov](mailto:kevin.hall@nih.gov); Twitter: @KevinH\_PhD

7

## 8 **SUMMARY**


9 Gut-derived hormones affect appetite and are thought to play an important role in body weight  
10 regulation. Dietary macronutrient composition can influence gut-derived appetite hormone  
11 concentrations, thereby providing theoretical basis for why some diets might facilitate weight  
12 loss better than others. We investigated postprandial gut-derived appetite hormones in 20  
13 inpatient adults after 2 weeks of eating either a low carbohydrate (LC) or a low fat (LF) diet  
14 followed by the alternate diet in random order. A LC meal resulted in significantly greater  
15 postprandial GLP-1, GIP, and PYY but lower ghrelin compared to an isocaloric LF meal (all  
16  $p \leq 0.02$ ). However, differences in gut-derived appetite hormones were incommensurate with  
17 subsequent ad libitum energy intake over the rest of the day, which was  $551 \pm 103$  kcal  
18 ( $p < 0.0001$ ) greater with the LC as compared to the LF diet. The effects of gut-derived appetite  
19 hormones on ad libitum energy intake can be dominated by other diet-related factors, at least in  
20 the short-term.

21

## 22 **Keywords**

23 Appetite; Energy Intake; Gut Hormones; Postprandial; Low Carbohydrate; Low Fat; Diet

24 **Graphical Abstract**



25

## 26 INTRODUCTION

27 Gut-derived hormones affect appetite. Ghrelin increases hunger and decreases after food  
28 intake, whereas satiation and satiety are induced by peptide YY (PYY), glucagon-like peptide-1  
29 (GLP-1), and perhaps glucose-dependent insulinotropic polypeptide (GIP) which are all  
30 increased after food intake.<sup>1-3</sup> These gut-derived appetite hormones have been theorized to play  
31 a role in the weight-loss that results from bariatric surgery<sup>4,5</sup> and agonists of GLP-1 and GIP  
32 receptors have become successful pharmacological treatments for obesity.<sup>6-8</sup> Circulating  
33 concentrations of gut-derived appetite hormones can be influenced by dietary macronutrient  
34 composition,<sup>9-13</sup> which provides a theoretical basis for why some diets may help facilitate weight  
35 loss better than others. We recently studied 20 inpatient adults who were exposed to two diets  
36 varying widely in the proportion of fat to carbohydrate for periods of 2 weeks each.<sup>14</sup> In a  
37 randomized crossover design, after 2 weeks of eating a low carbohydrate (LC) diet (75% fat,  
38 10% carbohydrate), the postprandial gut hormone responses to a representative LC liquid test  
39 meal were compared with an isocaloric low fat (LF) liquid test meal consumed after 2 weeks of  
40 eating a LF diet (10% fat, 75% carbohydrate). Subsequent ad libitum energy intake at lunch,  
41 dinner, and snacks for the rest of the day were measured to investigate whether postprandial  
42 responses were commensurate with subsequent intake during these dietary patterns.

43

## 44 RESULTS AND DISCUSSION

### 45 Gut hormone responses and subsequent energy intake

46 At the end of each ad libitum feeding period, the LC diet resulted in greater fasting  
47 concentrations of GLP-1 and GIP, but similar concentrations of PYY and leptin, and lower  
48 concentrations of total ghrelin and active ghrelin, when compared to the LF diet (**Table 1**).  
49 **Figure 1** demonstrates that the LC breakfast test meal delivered at the end of the ad libitum LC  
50 period resulted in greater mean postprandial plasma concentrations of active GLP-1 (LC meal:  
51  $6.44 \pm 0.78$  pg·mL<sup>-1</sup>, LF meal:  $2.46 \pm 0.26$  pg·mL<sup>-1</sup>;  $p < 0.0001$ ), total GIP (LC meal:  $578 \pm 60$  pg·mL<sup>-1</sup>,  
52 LF meal:  $319 \pm 37$  pg·mL<sup>-1</sup>;  $p = 0.0002$ ), and PYY (LC meal:  $65.6 \pm 5.6$  pg·mL<sup>-1</sup>, LF meal:  $50.7 \pm 3.8$   
53 pg·mL<sup>-1</sup>;  $p = 0.02$ ) whereas total ghrelin (LC meal:  $184 \pm 25$  pg·mL<sup>-1</sup>, LF meal:  $261 \pm 47$  pg·mL<sup>-1</sup>;  
54  $p = 0.0009$ ), active ghrelin (LC meal:  $91 \pm 9$  pg·mL<sup>-1</sup>, LF meal:  $232 \pm 28$  pg·mL<sup>-1</sup>;  $p < 0.0001$ ), and  
55 leptin (LC meal:  $26.9 \pm 6.5$  ng·mL<sup>-1</sup>, LF meal:  $35.2 \pm 7.5$  ng·mL<sup>-1</sup>;  $p = 0.01$ ) were lower as compared  
56 to an isocaloric LF breakfast test meal delivered at the end of the ad libitum LF period.

57

58 After the breakfast test meal, ad libitum energy intake was greater during the LC diet at lunch  
59 ( $244\pm 85$  kcal;  $p=0.001$ ) and dinner ( $193\pm 86$  kcal;  $p=0.04$ ), but not snacks ( $114\pm 63$  kcal;  $p=0.12$ ),  
60 such that the total ad libitum energy intake over the rest of the day was significantly greater  
61 ( $551\pm 103$  kcal;  $p<0.0001$ ) as compared to when the same participants consumed the LF diet  
62 (**Figure 2A**). Within each diet pattern, there were no significant correlations between  
63 subsequent ad libitum energy intake and the mean postprandial active GLP-1 (LC diet:  $r=-0.1$ ;  
64  $p=0.68$ , LF diet:  $r=-0.12$ ;  $p=0.60$ ), total GIP (LC diet:  $r=-0.08$ ;  $p=0.73$ , LF diet:  $r=0.23$ ;  $p=0.34$ ),  
65 PYY (LC diet:  $r=-0.23$ ;  $p=0.32$ , LF diet:  $r=-0.007$ ;  $p=0.98$ ), total ghrelin (LC diet:  $r=0.31$ ;  $p=0.19$ ,  
66 LF diet:  $r=0.32$ ;  $p=0.16$ ), active ghrelin (LC diet:  $r=0.20$ ;  $p=0.41$ , LF diet:  $r=0.07$ ;  $p=0.76$ ), or  
67 leptin (LC diet:  $r=-0.07$ ;  $p=0.77$ , LF diet:  $r=-0.26$ ;  $p=0.27$ ).

68

69 The present cohort had a wide range of body mass indices, therefore diet by BMI interactions  
70 were explored to investigate if any of the differences in gut hormone responses were driven by  
71 BMI (**Figure S1**). The only significant diet by BMI interaction was observed for active ghrelin,  
72 which was greater in LF than LC in individuals with a BMI below  $25 \text{ kg}\cdot\text{m}^{-2}$  ( $p<0.0001$ ), but was  
73 not significantly different in individuals with overweight ( $p=0.48$ ) or obesity ( $p=0.25$ ).

74

75 The observed differences in gut-derived appetite hormones during the LC test meal would be  
76 expected to result in reduced appetite and lower ad libitum energy intake as compared to the LF  
77 diet. However, the opposite result was observed, with the LC diet resulting in an additional  $\sim 500$   
78 kcal consumed over the remainder of the day following the test meal, as compared to the LF  
79 diet. This difference was similar to the overall  $\sim 700 \text{ kcal}\cdot\text{d}^{-1}$  difference between the diets  
80 averaged over two weeks.<sup>14</sup>

81

82 Concentrations of the adipokine leptin were commensurate with the direction of ad libitum  
83 energy intake differences for the LC and LF diets. The lower leptin following the LC diet (vs LF)  
84 is in agreement with previous evidence comparing a ketogenic low carbohydrate diet with an  
85 isocaloric diet moderate in both carbohydrate and fat.<sup>15</sup> The decrease in leptin following LC is  
86 likely explained by decreased insulin and glucose concentrations, which were lower in LC  
87 compared to LF.<sup>14</sup> Previous studies have shown that small increases in insulin induced by

88 glucose infusion of 2.5 mg·kg<sup>-1</sup>·min were sufficient to offset the decrease in leptin observed with  
89 16 hours of fasting<sup>16</sup> and 24 hours of ketogenic carbohydrate restriction reduced leptin  
90 concentrations independent from changes in ad libitum energy intake and preceding changes in  
91 adiposity.<sup>17</sup> Therefore, the evidence suggests that changes in carbohydrate availability, rather  
92 than energy intake or energy balance, are key for altering leptin concentrations. Decreased  
93 leptin would theoretically increase appetite, as has been associated following weight loss.<sup>18</sup>  
94 Whilst it is possible that leptin, as a longer-term appetite signal, overrides the transient signals  
95 from gut-derived hormones, leptin concentrations did not correlate with ad libitum energy intake  
96 in the present study, so it is likely that other diet-related factors are more important in this  
97 context.

98

### 99 **Influence of macronutrient composition on gut hormone response**

100 Although the LC and LF diets differed by more than just their macronutrient composition, it is  
101 likely that the differences in gut hormone responses were mainly due to macronutrient  
102 differences as previously reviewed.<sup>19,20</sup> Early evidence in humans suggested that small  
103 increases in GLP-1 were observed after isocaloric carbohydrate (glucose), fat (double cream),  
104 or protein (lean turkey) ingestion, whereas GIP only responded to carbohydrate and fat.<sup>21</sup>  
105 However, regardless of nutrient, the food matrix also plays a large role in determining  
106 postprandial responses as demonstrated by isocaloric ingestion of glucose eliciting greater  
107 GLP-1 and GIP responses than whole food sources of carbohydrate, including brown rice or  
108 pearl barley.<sup>21</sup> With regards to carbohydrate manipulation, the increase in PYY observed  
109 following LC in the present study resembles the results of a similar randomized crossover study  
110 in participants with obesity who consumed isocaloric low-carbohydrate or low-fat diets for one  
111 week before ingesting a representative breakfast meal.<sup>22</sup> Similarly, high-fat drinks (38%  
112 carbohydrate, 50% fat) increase postprandial GLP-1 and PYY responses, without differences in  
113 postprandial ghrelin responses, compared to isocaloric (590 kcal) low-fat, high-carbohydrate  
114 drinks (84% carbohydrate, 3% fat), but these differences did not translate into differences in ad  
115 libitum energy intake in a subsequent lunch meal.<sup>10</sup> Instead, ad libitum intake was associated  
116 with ghrelin responses, which contrasts with our results because total and active ghrelin were  
117 reduced with the LC diet in comparison to the LF diet and did not correlate with energy intake.

118

119 Macronutrient manipulation, with food volume and energy density controlled, has been shown to  
120 alter postprandial GLP-1, GIP, PYY, active ghrelin, and total ghrelin responses, but did not alter  
121 subjective hunger or subsequent energy intake.<sup>9,12,13</sup> Over the course of our study, the LF diet  
122 resulted in  $\sim 700$  kcal·d<sup>-1</sup> less ad libitum energy intake as compared to the LC diet without  
123 significant differences in self-reported appetite.<sup>14</sup> Because postprandial responses of gut-  
124 derived appetite hormones depend on the amount of food consumed,<sup>23,24</sup> the expected diet  
125 differences in postprandial ghrelin, GLP-1, GIP, and PYY during the ad libitum period would  
126 likely be even greater than we observed following the isocaloric meal tests and further  
127 emphasizes that the expected effects of these appetite hormone differences were dominated by  
128 other diet differences.

129

### 130 **Diet-related factors affecting energy intake beyond gut hormones**

131 Recent analysis of the meal characteristics that affect energy intake from our inpatient feeding  
132 studies suggests that energy density, eating rate, and proportion of hyper-palatable foods are  
133 positively associated with meal energy intake.<sup>25</sup> Greater dietary energy density has consistently  
134 been shown to increase energy intake in short-term interventions.<sup>26</sup> The LC diet of the present  
135 study had about double the energy density of the LF diet and mediated around 25% of the diet  
136 effect on meal energy intake.<sup>25</sup> A quicker eating rate increases energy intake of presented  
137 meals without altering subsequent hunger.<sup>27</sup> Eating rate could be related to sensory and  
138 physical properties of foods, like food texture;<sup>28</sup> for example, softer, less solid, less viscous  
139 foods are associated with increased eating rate.<sup>29</sup> Eating rate in grams per minute was quicker  
140 in the LF meals at lunch ( $29 \pm 9$  g·min<sup>-1</sup>,  $p < 0.0001$ ) and dinner ( $14 \pm 9$  g·min<sup>-1</sup>,  $p = 0.009$ ) on the test  
141 meal day, compared to LC, so this factor is unlikely to explain our observations of increased  
142 energy intake on the LC test meal day. The volume and mass of food ingested is closely related  
143 to energy density, which may alter gastric distension and contribute to changes in gut hormone  
144 responses to meals.<sup>30</sup> The mass of food eaten ad libitum was significantly greater following the  
145 LF diet at lunch and dinner, but not snacks (**Figure 2B**), compared to LC. This total difference  
146 across the day was consistent with the overall  $\sim 667$  g·d<sup>-1</sup> difference between the diets averaged  
147 over two weeks.<sup>14</sup> Within each diet pattern, there were no significant correlations between  
148 postprandial gut hormone responses following the liquid test meals and subsequent mass of  
149 food eaten at lunch (first subsequent meal) or throughout the day of the test meal (**Table S1**),  
150 apart from a moderate negative correlation between food mass intake at lunch in the LF diet  
151 and leptin. Hyper-palatable foods have recently been defined using quantitative thresholds of

152 nutrient combinations that may drive excess intake; 1) fat and sugar (>20% energy, >20%  
153 energy), 2) fat and sodium (>20% of energy, >0.3% by weight), and 3) carbohydrates and  
154 sodium (>40% energy, >0.3% by weight).<sup>31</sup> Across the entire 2 weeks, meals in the LC diet had  
155 a greater proportion of hyper-palatable foods than the LF diet, which may have mediated around  
156 14% of the diet effect on meal energy intake.<sup>25</sup> The availability of hyperpalatable foods in the US  
157 food system, by this definition, has increased from around 49% to around 69% in 30 years.<sup>32</sup>  
158 Emerging cross-sectional evidence suggests that hyper-palatable foods may be more  
159 rewarding.<sup>33</sup> More work is required to determine the utility of quantitative definitions of hyper-  
160 palatability and their influence on food intake. Whilst the alternative diet-related factors  
161 discussed may often be inter-related in real world settings, it is important for future work to  
162 isolate these diet-related factors and test their contribution to ad libitum energy intake in  
163 different dietary contexts (e.g. macronutrient manipulation or processing).

164

#### 165 **Comparisons between diet and pharmacological or surgical interventions**

166 Discordance between gut hormone responses and energy intake in the present study may  
167 appear to contradict the recent success of pharmacological gut hormone mimetics, including  
168 GLP-1 receptor agonists, but quantitative considerations of dose and exposure reconcile our  
169 findings. Specifically, the estimated active GLP-1 steady state average exposure concentration,  
170  $C_{avg}$ , for the present study had mean (95% CI) values of 0.034 (0.029, 0.043)  $\text{nmol}\cdot\text{L}^{-1}$  for LF  
171 and 0.086 (0.071, 0.113)  $\text{nmol}\cdot\text{L}^{-1}$  for LC, which are orders of magnitude lower than the  $C_{avg}$  of  
172 both oral and subcutaneous semaglutide ranging from  $\sim 3$   $\text{nmol}\cdot\text{L}^{-1}$  up to  $\sim 30$   $\text{nmol}\cdot\text{L}^{-1}$  with oral  
173 and subcutaneous semaglutide, respectively (**Figure 3A**).<sup>34</sup> Such high  $C_{avg}$  with  
174 pharmacological treatment is due to the long half-life of semaglutide which has a similar binding  
175 affinity to the GLP-1 receptor as native GLP-1,<sup>35</sup> whereas the half-life of endogenous GLP-1 and  
176 GIP is minutes in humans.<sup>36</sup> Unlike pharmacological intervention, diet-induced changes in gut  
177 hormone concentrations reflect conjoint changes of multiple hormones in a complex signalling  
178 system, so the quantitative exposure of GLP-1 from diet and pharmacological interventions  
179 cannot be compared directly, but this comparison highlights that the magnitude of change in  
180 GLP-1 from diet is not comparable to that of pharmacological interventions even with the  
181 concurrent changes of other hormones.

182

183 Pharmacological engagement of the GLP-1 receptor (e.g. exogenous GLP-1) may act differently  
184 from nutrient-stimulated gut hormones (e.g. endogenous GLP-1). For example, endogenous  
185 GLP-1 may affect the hypothalamus through neuronal signaling from the gut to brain via solitary  
186 tract neurons, whereas exogenous GLP-1 receptor agonists may directly engage hypothalamic  
187 and brainstem GLP-1 receptors.<sup>6</sup> Further complicating this, GLP-1 can be produced centrally in  
188 brain regions which may directly alter appetite independent from diet-induced gut hormone  
189 secretion.<sup>37</sup> With this context, changes in endogenous gut hormone concentrations induced by  
190 diet may be not be potent enough to affect energy intake. Indeed, mouse models that knockout  
191 the GLP-1 receptor,<sup>38</sup> or delete intestinal GLP-1 production through GNG gene knockout,<sup>39</sup> do  
192 not result in a body weight or food intake phenotype, suggesting that endogenous GLP-1 has a  
193 limited effect on appetite in the normal physiological range.

194  
195 Some forms of bariatric surgery result in substantial increases in postprandial GLP-1 and  
196 PYY,<sup>40-42</sup> likely due to altered gastric emptying and intestinal nutrient delivery. The magnitude of  
197 post-surgical changes in postprandial gut hormone responses might be mechanistically linked to  
198 reduced appetite and energy intake. Infusion of GLP-1, PYY, and oxyntomodulin in healthy  
199 participants that mimics the concentrations observed following Roux-en-Y gastric bypass  
200 reduced energy intake at lunch and dinner by ~400 kcal.<sup>3</sup> The active GLP-1 and PYY  
201 concentrations achieved were around 26 pmol·L<sup>-1</sup> (85 pg·mL<sup>-1</sup>) and 80 pmol·L<sup>-1</sup> (320 pg·mL<sup>-1</sup>)  
202 respectively. For active GLP-1, these concentrations are around 13-fold and 35-fold greater  
203 than mean postprandial concentrations following the LC and LF meals in the present study, and  
204 for PYY they are around 5-fold and 6-fold greater (**Figure 3B**). Infusing GLP-1 to achieve  
205 concentrations comparable with the LC condition of the present study (~15 pg·mL<sup>-1</sup>) delays  
206 gastric emptying without suppressing subjective appetite and ad libitum intake.<sup>43</sup>  
207 Supraphysiological concentrations of GLP-1 achieved by infusion (~25 to 30 pg·mL<sup>-1</sup>) suppress  
208 subjective appetite, but effects on subsequent ad libitum energy intake are modest compared  
209 with higher concentrations (~100 to 240 kcal).<sup>44,45</sup> Together, infusion studies indicate a dose-  
210 response relationship between active GLP-1 and suppression of appetite,<sup>46</sup> and suggest that  
211 substantially greater increases in gut hormone concentrations are required to have meaningful  
212 effects on appetite and energy intake, likely greater than is achievable by diet interventions  
213 alone.

214



## 215 **Limitations and considerations**

216 A limitation of the current study is that participants had no choice regarding the foods available  
217 for consumption. They could only choose the quantity of the foods eaten. While the gut-derived  
218 appetite hormones were not a dominant factor determining energy intake in this setting, it is  
219 possible that such differences in appetite hormones in a real-world setting might alter food  
220 choices at subsequent meals and thereby alter energy intake. Another limitation is that we used  
221 isocaloric liquid test meals that matched the macronutrient composition of the overall LC and LF  
222 diets. These test meals may have not been adequately representative of the effects of meals  
223 with solid foods. Furthermore, the results reported in this study were from analyses that were  
224 not pre-specified as primary or secondary outcomes of the main study and are hence  
225 exploratory in nature. Nevertheless, our study suggests that differences in dietary factors like  
226 energy density or proportion of hyper-palatable foods may play a greater role in appetite  
227 regulation than endogenous gut-derived appetite hormones, at least in the short term. Future  
228 research should aim to identify such diet differences that influence energy intake and evaluate  
229 whether their effects and their potential discordance with gut-derived appetite hormones persist  
230 over time.

231 **ACKNOWLEDGEMENTS**

232 This work was supported by the Intramural Research Program of the NIH, National Institute of  
233 Diabetes & Digestive & Kidney Diseases under award number 1ZIADK013037. We thank the  
234 nursing and nutrition staff at the NIH Metabolic Clinical Research Unit for their invaluable  
235 assistance with this study. We thank the study participants for their invaluable contribution.

236 **AUTHOR CONTRIBUTIONS**

237 KDH designed the study, MW performed the biochemical analyses, JG and KDH analyzed the  
238 data, AH, CMS, JG, and KDH interpreted the data, drafted the manuscript, and approved the  
239 final version.


240 **DECLARATION OF INTERESTS**

241 The authors declare no competing interests.

242 **Figures**


243 **Figure 1. Postprandial responses to isocaloric low carbohydrate (LC) or low fat (LF) meals**  
244 **following habituation to each diet in a randomized crossover design. Mean (range) of energy in**  
245 **the test meals was 777 (532 to 1043) kcal. Data are mean  $\pm$  SEM. n=20. *p*-values from paired t-test**  
246 **of mean postprandial plasma concentrations.**

- 247 (A) active glucagon-like peptide-1 (GLP-1)
- 248 (B) total glucose-dependent insulinotropic polypeptide (GIP)
- 249 (C) peptide YY (PYY)
- 250 (D) leptin
- 251 (E) total ghrelin
- 252 (F) active ghrelin




253

254 **Figure 2. Total intake, and intake from lunch, dinner, and snacks throughout the day after**  
255 **isocaloric low carbohydrate (LC) or low fat (LF) meals following habituation to each diet in a**  
256 **randomized crossover design. Mean (range) of energy in the test meals was 777 (532 to 1043) kcal.**  
257 **Data are mean  $\pm$  SEM and individual responses. n=20. p-values from paired t-test or Wilcoxon test.**  
258 **(A) Energy intake (EI) (kcal)**  
259 **(B) Mass intake (g)**



260

261 **Figure 3. Comparisons between dietary macronutrient induced changes in gut hormone**  
262 **responses and pharmacological or bariatric surgery induced changes.**  
263 **(A) estimated mean active GLP-1 steady state average exposure concentrations,  $C_{avg}$ , achieved by**  
264 **low carbohydrate (LC) or low fat (LF) diet were orders of magnitude lower than the both oral and**  
265 **subcutaneous semaglutide using values median (90% exposure ranges) from Overgaard et al.<sup>34</sup>**  
266 **(B) peak active GLP-1 and PYY concentrations following a LC or LF test meal were orders of**  
267 **magnitude lower than peak concentrations observed during a mixed-meal test following Roux-en-**  
268 **Y Gastric Bypass surgery (RYGB) using data from Tan et al.<sup>3</sup> Data are mean  $\pm$  SEM.**



269

270 **Tables**

271 **Table 1. Fasting concentrations of gut-derived appetite hormones and leptin in the second week**  
272 **of low carbohydrate (LC) or low fat (LF) diet. Data are mean  $\pm$  SEM, n=20.**  
273

	LC	LF	<i>p</i> value LC vs LF
Active GLP-1 (pg·mL <sup>-1</sup> )	0.96 $\pm$ 0.14	0.61 $\pm$ 0.06	0.01
Total GIP (pg·mL <sup>-1</sup> )	80 $\pm$ 13	56 $\pm$ 8	0.03
PYY (pg·mL <sup>-1</sup> )	38.2 $\pm$ 3.2	38.0 $\pm$ 3.7	0.94
Total ghrelin (pg·mL <sup>-1</sup> )	263 $\pm$ 48	329 $\pm$ 55	0.004
Active ghrelin (pg·mL <sup>-1</sup> )	116 $\pm$ 21	238 $\pm$ 30	0.0002
Leptin (ng·mL <sup>-1</sup> )	28.2 $\pm$ 6.7	33.5 $\pm$ 7.8	0.39

274

275 **STAR Methods**

276 **KEY RESOURCES TABLE**

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Biological samples		
Human serum and plasma	NCT03878108	<a href="https://www.clinicaltrials.gov/study/NCT03878108">https://www.clinicaltrials.gov/study/NCT03878108</a>
Critical commercial assays		
U-plex multiplex assay	Meso Scale Diagnostics	K15281K
Deposited data		
Raw human data	This paper	<a href="https://osf.io/fjyq/">https://osf.io/fjyq/</a>

277

278 **RESOURCE AVAILABILITY**

279 **Lead contact**

280 Further information and requests for resources and reagents should be directed to and will be  
281 fulfilled by the Lead Contact Dr Kevin Hall ([kevin.hall@nih.gov](mailto:kevin.hall@nih.gov)).

282 **Materials availability**

283 This study did not generate new unique reagents.

284 **Data and code availability**

285 De-identified data have been deposited at <https://osf.io/fjyq/> and are publicly available as of the  
286 date of publication. This paper does not report original code.

287

288 **EXPERIMENTAL MODEL AND STUDY PARTICIPANT DETAILS**

289 These data are exploratory endpoints from a registered clinical trial conducted at the Metabolic  
290 Clinical Research Unit at the NIH Clinical Center and approved by the institutional board of the  
291 National Institute of Diabetes & Digestive & Kidney Diseases (NCT03878108). Detailed  
292 methods have been published previously.<sup>14</sup> Participants completed a single four week stay and  
293 completed 2 diets in a randomized order. One diet was an animal-based, ketogenic, low  
294 carbohydrate (LC) diet with ~10% of energy from carbohydrates, ~75% from fat and the other  
295 diet was a plant-based, low fat (LF) diet with ~10% of energy from fat, ~75% from carbohydrate.  
296 Inclusion criteria were male and female adults age 18–50 years; weight stable (within 5% in past

297 6 months); body mass index  $\geq 20 \text{ kg}\cdot\text{m}^{-2}$ ; body weight  $\geq 53 \text{ kg}$ ; able to complete daily bouts of  
298 stationary cycling at a moderate rate and intensity with a heart rate (HR) equal to or greater than  
299  $0.3 \times (220 - \text{age} - \text{HR}_{\text{rest}}) + \text{HR}_{\text{rest}}$  but not exceeding  
300  $0.4 \times (220 - \text{age} - \text{HR}_{\text{rest}}) + \text{HR}_{\text{rest}}$  and no signs of arrhythmia. Exclusion criteria  
301 were evidence of metabolic or cardiovascular disease or disease that may influence metabolism  
302 (for example cancer, diabetes, thyroid disease); taking any prescription medication or other drug  
303 that may influence metabolism (for example diet/weight-loss medication, asthma medication,  
304 blood pressure medication, psychiatric medications, corticosteroids or other medications at the  
305 discretion of the study team); positive pregnancy test or lactation as determined by volunteer  
306 report (women only); participating in a regular exercise program ( $>2 \text{ h}\cdot\text{week}^{-1}$  of vigorous  
307 activity); hematocrit  $<37\%$  for women and  $<40\%$  for men; habitual caffeine consumption  
308  $>300 \text{ mg}\cdot\text{d}^{-1}$ ; regular use of alcohol ( $>2$  drinks per day), tobacco (smoking or chewing),  
309 amphetamines, cocaine, heroin or marijuana over past 6 months; psychological conditions such  
310 as (but not limited to) eating disorders, claustrophobia, clinical depression, bipolar disorders, as  
311 determined by investigators after reviewing the results of the DSM-5 Self-Rated Level 1 Cross-  
312 Cutting Symptom Measure; past or present history of claustrophobia; implants, devices or  
313 foreign objects implanted in the body that interfere with the magnetic resonance procedures;  
314 strict dietary concerns (for example vegetarian or kosher diet, food allergies) as determined by  
315 investigators after reviewing the results of the Food Frequency Questionnaire; volunteers  
316 unwilling or unable to give informed consent; and non-English speakers owing to unavailability  
317 of required questionnaires in other languages. Participants were 20 adults (male  $n=11$ , female  
318  $n=9$ ; mean $\pm$ SD, age  $30\pm 6$  years; body mass  $80.8\pm 18.2 \text{ kg}$ ; body mass index  $27.8\pm 5.9 \text{ kg}\cdot\text{m}^{-2}$ ; fat  
319 mass  $26.9\pm 11.2 \text{ kg}$ ; body fat percentage  $32.8\pm 9.8\%$ ; resting energy expenditure  $1550\pm 287$   
320  $\text{kcal}\cdot\text{d}^{-1}$ ).

321

## 322 **METHOD DETAILS**

323 At the end of the second inpatient week of consuming either the ad libitum low carbohydrate  
324 (LC) or low fat (LF) diets and after an overnight fast, participants consumed liquid meals  
325 matching the macronutrient content of the prevailing diet and amounting to 30% of the  
326 estimated daily calorie requirements as determined by 1.6 multiplied by the resting energy  
327 expenditure measured at screening. Mean (range) of energy in the test meals was 777 (532 to  
328 1043) kcal. The LC test meal was 10% carbohydrate, 75% fat, and 15% protein whereas the LF



329 test meal was 75% carbohydrate, 10% fat, and 15% protein. Blood samples were obtained at 0,  
330 10, 20, 30, 60, 90, 120, 180, 240, 300, and 360 minutes after the meals in tubes containing a  
331 protease inhibitor cocktail (including DPPIV inhibitor and aprotinin) to measure GLP-1, GIP,  
332 PYY, total ghrelin, active ghrelin, and leptin using multiplex immunoassays (Meso Scale  
333 Diagnostics).

334

335 After the breakfast mixed meal tests, ad libitum food intake was measured over the rest of the  
336 day including lunch, dinner, and snacks by weighing the remaining food and beverages to  
337 calculate the amount of each food consumed and energy intake was calculated using ProNutra  
338 software (v.3.4, Viocare) with nutrient values derived from the USDA National Nutrient Database  
339 for Standard Reference, Release 26 and the USDA Food and Nutrient Database for Dietary  
340 Studies, 4.0. Statistical analyses were performed using SAS (v.9.4; SAS Institute) and Prism  
341 (v.9.5.0; GraphPad). Mean plasma concentrations were calculated by dividing total area under  
342 the curve (tAUC) by 360 minutes. Active GLP-1  $C_{avg}$  was estimated by multiplying the 6-hour  
343 postprandial tAUC by 3 (18 h) and multiplying the postabsorptive (fasting) concentration by 360  
344 minutes (6 h), to get 24-hour exposure, and dividing by 24. The conversion factor used for GLP-  
345 1 was  $1 \text{ pmol}\cdot\text{L}^{-1} = 3.297 \text{ pg}\cdot\text{mL}^{-1}$ . Data were checked for normality using Shapiro-Wilk test,  
346 differences between conditions were assessed using paired t-tests for normally distributed and  
347 Wilcoxon tests for non-normally distributed data. Simple linear correlation was used to explore  
348 associations between gut hormone responses and ad libitum energy intake. Diet by BMI  
349 interactions were checked using 2-way ANOVA, with post-hoc Bonferroni tests used to identify  
350 differences. Significance was accepted as  $p \leq 0.05$ .

351 **SUPPLEMENTAL INFORMATION**

352


353 **Discordance between gut-derived appetite hormones and energy intake in humans**

354 **Aaron Hengist, Christina M. Sciarrillo, Juen Guo, Mary Walter, Kevin D. Hall**

355

356 This document contains 1 supplemental figure and 1 supplemental table.

357 **Figure S1. Gut hormone responses sub-divided into body mass index categories. Data are mean  $\pm$**   
358 **SEM and individual responses. n=20. p-values from two-way ANOVA of diet by BMI category.**  
359 **(A) Participants split by BMI category**  
360 **(B) Total energy intake**  
361 **(C) active glucagon-like peptide-1 (GLP-1)**  
362 **(D) total glucose-dependent insulinotropic polypeptide (GIP)**  
363 **(E) peptide YY (PYY)**  
364 **(F) leptin**  
365 **(G) total ghrelin**  
366 **(H) active ghrelin**



367

368 **Table S1. Correlations between mean postprandial responses to isocaloric low carbohydrate (LC)**  
 369 **or low fat (LF) meals following habituation to each diet in a randomized crossover design with the**  
 370 **subsequent mass intake in the lunch meal and total intake across the day following the test meal.**  
 371

Mean postprandial concentrations	Subsequent <b>lunch</b> mass intake during test meal day		Subsequent <b>total</b> mass intake during test meal day	
	LC	LF	LC	LF
Active GLP-1	-0.11 (0.63)	-0.21 (0.37)	-0.12 (0.62)	-0.14 (0.55)
Total GIP	-0.20 (0.39)	-0.06 (0.79)	-0.15 (0.54)	0.22 (0.36)
PYY	-0.22 (0.36)	0.07 (0.76)	-0.33 (0.15)	0.10 (0.68)
Total ghrelin	-0.30 (0.20)	0.44 (0.0504)	-0.06 (0.82)	0.38 (0.10)
Active ghrelin	0.004 (0.99)	0.35 (0.13)	0.06 (0.81)	0.20 (0.39)
Leptin	-0.06 (0.81)	<b>-0.48</b> <b>(0.03)</b>	-0.07 (0.76)	-0.40 (0.08)

372 Data are Pearson's r (p-value). n=20.

## 373 REFERENCES

- 374 1. Samms, R.J., Goghlan, M.P., and Sloop, K.W. (2020). How May GIP Enhance the Therapeutic Efficacy of  
375 GLP-1? *Trends in Endocrinology and Metabolism* *31*, 410-421. 10.1016/j.tem.2020.02.006.
- 376 2. Sato, T., Nakamura, Y., Shiimura, Y., Ohgusu, H., Kangawa, K., and Kojima, M. (2012). Structure,  
377 regulation and function of ghrelin. *J Biochem* *151*, 119-128. 10.1093/jb/mvr134.
- 378 3. Tan, T., Behary, P., Tharakan, G., Minnion, J., Al-Najim, W., Albrechtsen, N.J.W., Holst, J.J., and Bloom,  
379 S.R. (2017). The Effect of a Subcutaneous Infusion of GLP-1, OXM, and PYY on Energy Intake and  
380 Expenditure in Obese Volunteers. *The Journal of clinical endocrinology and metabolism* *102*,  
381 2364-2372. 10.1210/jc.2017-00469.
- 382 4. Holst, J.J., Madsbad, S., Bojsen-Moller, K.N., Svane, M.S., Jorgensen, N.B., Dirksen, C., and  
383 Martinussen, C. (2018). Mechanisms in bariatric surgery: Gut hormones, diabetes resolution,  
384 and weight loss. *Surg Obes Relat Dis* *14*, 708-714. 10.1016/j.soard.2018.03.003.
- 385 5. Troke, R.C., Tan, T.M., and Bloom, S.R. (2014). The future role of gut hormones in the treatment of  
386 obesity. *Ther Adv Chronic Dis* *5*, 4-14. 10.1177/2040622313506730.
- 387 6. Drucker, D.J., and Holst, J.J. (2023). The expanding incretin universe: from basic biology to clinical  
388 translation. *Diabetologia*. 10.1007/s00125-023-05906-7.
- 389 7. Jastreboff, A.M., Aronne, L.J., Ahmad, N.N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S.,  
390 Liu, B., Bunck, M.C., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. *N Engl J*  
391 *Med* *387*, 205-216. 10.1056/NEJMoa2206038.
- 392 8. Wilding, J.P.H., Batterham, R.L., Calanna, S., Davies, M., Van Gaal, L.F., Lingvay, I., McGowan, B.M.,  
393 Rosenstock, J., Tran, M.T.D., Wadden, T.A., et al. (2021). Once-Weekly Semaglutide in Adults  
394 with Overweight or Obesity. *N Engl J Med* *384*, 989-1002. 10.1056/NEJMoa2032183.
- 395 9. Foster-Schubert, K.E., Overduin, J., Prudom, C.E., Liu, J., Callahan, H.S., Gaylinn, B.D., Thorner, M.O.,  
396 and Cummings, D.E. (2008). Acyl and total ghrelin are suppressed strongly by ingested proteins,  
397 weakly by lipids, and biphasically by carbohydrates. *The Journal of clinical endocrinology and*  
398 *metabolism* *93*, 1971-1979. 10.1210/jc.2007-2289.
- 399 10. Gibbons, C., Caudwell, P., Finlayson, G., Webb, D.L., Hellstrom, P.M., Naslund, E., and Blundell, J.E.  
400 (2013). Comparison of postprandial profiles of ghrelin, active GLP-1, and total PYY to meals  
401 varying in fat and carbohydrate and their association with hunger and the phases of satiety. *The*  
402 *Journal of clinical endocrinology and metabolism* *98*, E847-855. 10.1210/jc.2012-3835.
- 403 11. Helou, N., Obeid, O., Azar, S.T., and Hwalla, N. (2008). Variation of postprandial PYY 3-36 response  
404 following ingestion of differing macronutrient meals in obese females. *Ann Nutr Metab* *52*, 188-  
405 195. 10.1159/000138122.
- 406 12. Raben, A., Agerholm-Larsen, L., Flint, A., Holst, J.J., and Astrup, A. (2003). Meals with similar energy  
407 densities but rich in protein, fat, carbohydrate, or alcohol have different effects on energy  
408 expenditure and substrate metabolism but not on appetite and energy intake. *Am J Clin Nutr* *77*,  
409 91-100. DOI 10.1093/ajcn/77.1.91.
- 410 13. van der Klaauw, A.A., Keogh, J.M., Henning, E., Trowse, V.M., Dhillon, W.S., Ghatei, M.A., and Farooqi,  
411 I.S. (2013). High Protein Intake Stimulates Postprandial GLP1 and PYY Release. *Obesity* *21*, 1602-  
412 1607. 10.1002/oby.20154.
- 413 14. Hall, K.D., Guo, J., Courville, A.B., Boring, J., Brychta, R., Chen, K.Y., Darcey, V., Forde, C.G., Gharib,  
414 A.M., Gallagher, I., et al. (2021). Effect of a plant-based, low-fat diet versus an animal-based,  
415 ketogenic diet on ad libitum energy intake. *Nat Med* *27*, 344-353. 10.1038/s41591-020-01209-1.
- 416 15. Hall, K.D., Chen, K.Y., Guo, J., Lam, Y.Y., Leibel, R.L., Mayer, L.E., Reitman, M.L., Rosenbaum, M.,  
417 Smith, S.R., Walsh, B.T., and Ravussin, E. (2016). Energy expenditure and body composition  
418 changes after an isocaloric ketogenic diet in overweight and obese men. *Am J Clin Nutr* *104*,  
419 324-333. 10.3945/ajcn.116.133561.

- 420 16. Sonnenberg, G.E., Krakower, G.R., Hoffmann, R.G., Maas, D.L., Hennes, M.M., and Kissebah, A.H.  
421 (2001). Plasma leptin concentrations during extended fasting and graded glucose infusions:  
422 relationships with changes in glucose, insulin, and FFA. *The Journal of clinical endocrinology and*  
423 *metabolism* *86*, 4895-4900. 10.1210/jcem.86.10.7951.
- 424 17. Hengist, A., Davies, R.G., Rogers, P.J., Brunstrom, J.M., van Loon, L.J.C., Walhin, J.P., Thompson, D.,  
425 Koumanov, F., Betts, J.A., and Gonzalez, J.T. (2022). Restricting sugar or carbohydrate intake  
426 does not impact physical activity level or energy intake over 24 h despite changes in substrate  
427 use: a randomised crossover study in healthy men and women. *Eur J Nutr.* 10.1007/s00394-022-  
428 03048-x.
- 429 18. Keim, N.L., Stern, J.S., and Havel, P.J. (1998). Relation between circulating leptin concentrations and  
430 appetite during a prolonged, moderate energy deficit in women. *Am J Clin Nutr* *68*, 794-801.  
431 10.1093/ajcn/68.4.794.
- 432 19. Bodnaruc, A.M., Prud'homme, D., Blanchet, R., and Giroux, I. (2016). Nutritional modulation of  
433 endogenous glucagon-like peptide-1 secretion: a review. *Nutr Metab (Lond)* *13*, 92.  
434 10.1186/s12986-016-0153-3.
- 435 20. Watkins, J.D., Koumanov, F., and Gonzalez, J.T. (2021). Protein- and Calcium-Mediated GLP-1  
436 Secretion: A Narrative Review. *Adv Nutr* *12*, 2540-2552. 10.1093/advances/nmab078.
- 437 21. Elliott, R.M., Morgan, L.M., Tredger, J.A., Deacon, S., Wright, J., and Marks, V. (1993). Glucagon-like  
438 peptide-1 (7-36)amide and glucose-dependent insulinotropic polypeptide secretion in response  
439 to nutrient ingestion in man: acute post-prandial and 24-h secretion patterns. *J Endocrinol* *138*,  
440 159-166. 10.1677/joe.0.1380159.
- 441 22. Essah, P.A., Levy, J.R., Sistrun, S.N., Kelly, S.M., and Nestler, J.E. (2007). Effect of macronutrient  
442 composition on postprandial peptide YY levels. *Journal of Clinical Endocrinology & Metabolism*  
443 *92*, 4052-4055. 10.1210/jc.2006-2273.
- 444 23. Hengist, A., Edinburgh, R.M., Davies, R.G., Walhin, J.P., Buniam, J., James, L.J., Rogers, P.J., Gonzalez,  
445 J.T., and Betts, J.A. (2020). Physiological responses to maximal eating in men. *The British journal*  
446 *of nutrition* *124*, 407-417. 10.1017/S0007114520001270.
- 447 24. Lewis, H.B., Ahern, A.L., Solis-Trapala, I., Walker, C.G., Reimann, F., Gribble, F.M., and Jebb, S.A.  
448 (2015). Effect of reducing portion size at a compulsory meal on later energy intake, gut  
449 hormones, and appetite in overweight adults. *Obesity (Silver Spring)* *23*, 1362-1370.  
450 10.1002/oby.21105.
- 451 25. Fazzino, T.L., Courville, A.B., Guo, J., and Hall, K.D. (2023). Ad libitum meal energy intake is positively  
452 influenced by energy density, eating rate and hyper-palatable food across four dietary patterns.  
453 *Nat Food.* 10.1038/s43016-022-00688-4.
- 454 26. Robinson, E., Khuttan, M., McFarland-Lesser, I., Patel, Z., and Jones, A. (2022). Calorie reformulation:  
455 a systematic review and meta-analysis examining the effect of manipulating food energy density  
456 on daily energy intake. *Int J Behav Nutr Phy* *19*. ARTN 48  
457 10.1186/s12966-022-01287-z.
- 458 27. Robinson, E., Almiron-Roig, E., Rutters, F., de Graaf, C., Forde, C.G., Smith, C.T., Nolan, S.J., and Jebb,  
459 S.A. (2014). A systematic review and meta-analysis examining the effect of eating rate on energy  
460 intake and hunger. *Am J Clin Nutr* *100*, 123-151. 10.3945/ajcn.113.081745.
- 461 28. Forde, C.G., and de Graaf, K. (2022). Influence of Sensory Properties in Moderating Eating Behaviors  
462 and Food Intake. *Frontiers in Nutrition* *9*. ARTN 841444  
463 10.3389/fnut.2022.841444.
- 464 29. Appleton, K.M., Newbury, A., Almiron-Roig, E., Yeomans, M.R., Brunstrom, J.M., de Graaf, K., Geurts,  
465 L., Kildegaard, H., and Vinoy, S. (2021). Sensory and physical characteristics of foods that impact

- 466 food intake without affecting acceptability: Systematic review and meta-analyses. *Obesity*  
467 *Reviews* 22. 10.1111/obr.13234.
- 468 30. Cummings, D.E., and Overduin, J. (2007). Gastrointestinal regulation of food intake. *The Journal of*  
469 *clinical investigation* 117, 13-23. 10.1172/JCI30227.
- 470 31. Fazzino, T.L., Rohde, K., and Sullivan, D.K. (2019). Hyper-Palatable Foods: Development of a  
471 Quantitative Definition and Application to the US Food System Database. *Obesity* 27, 1761-  
472 1768. 10.1002/oby.22639.
- 473 32. Demeke, S., Rohde, K., Chollet-Hinton, L., Sutton, C., Kong, K.L., and Fazzino, T.L. (2023). Change in  
474 hyper-palatable food availability in the US food system over 30 years: 1988-2018. *Public health*  
475 *nutrition* 26, 182-189. Pii S1368980022001227  
10.1017/S1368980022001227.
- 476 33. Fazzino, T.L., Bjorlie, K., Rohde, K., Smith, A., and Yi, R. (2022). Choices Between Money and Hyper-  
477 Palatable Food: Choice Impulsivity and Eating Behavior. *Health Psychol* 41, 538-548.  
478 10.1037/hea0001185.
- 479 34. Overgaard, R.V., Hertz, C.L., Ingwersen, S.H., Navarria, A., and Drucker, D.J. (2021). Levels of  
480 circulating semaglutide determine reductions in HbA1c and body weight in people with type 2  
481 diabetes. *Cell Rep Med* 2, 100387. 10.1016/j.xcrm.2021.100387.
- 482 35. Overgaard, R.V., Navarria, A., Ingwersen, S.H., Baekdal, T.A., and Kildemoes, R.J. (2021). Clinical  
483 Pharmacokinetics of Oral Semaglutide: Analyses of Data from Clinical Pharmacology Trials. *Clin*  
484 *Pharmacokinet* 60, 1335-1348. 10.1007/s40262-021-01025-x.
- 485 36. Meier, J.J., Nauck, M.A., Kranz, D., Holst, J.J., Deacon, C.F., Gaeckler, D., Schmidt, W.E., and Gallwitz,  
486 B. (2004). Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric  
487 inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects.  
488 *Diabetes* 53, 654-662. 10.2337/diabetes.53.3.654.
- 489 37. Daniels, D., and Mietlicki-Baase, E.G. (2019). Glucagon-Like Peptide 1 in the Brain: Where Is It  
490 Coming From, Where Is It Going? *Diabetes* 68, 15-17. 10.2337/dbi18-0045.
- 491 38. Scrocchi, L.A., Brown, T.J., McClusky, N., Brubaker, P.L., Auerbach, A.B., Joyner, A.L., and Drucker,  
492 D.J. (1996). Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-  
493 like peptide 1 receptor gene. *Nat Med* 2, 1254-1258. 10.1038/nm1196-1254.
- 494 39. Song, Y., Koehler, J.A., Baggio, L.L., Powers, A.C., Sandoval, D.A., and Drucker, D.J. (2019). Gut-  
495 Proglucagon-Derived Peptides Are Essential for Regulating Glucose Homeostasis in Mice. *Cell*  
496 *Metab* 30, 976-986 e973. 10.1016/j.cmet.2019.08.009.
- 497 40. Lampropoulos, C., Alexandrides, T., Tsochatzis, S., Kehagias, D., and Kehagias, I. (2021). Are the  
498 Changes in Gastrointestinal Hormone Secretion Necessary for the Success of Bariatric Surgery? A  
499 Critical Review of the Literature. *Obes Surg* 31, 4575-4584. 10.1007/s11695-021-05568-7.
- 500 41. Papamargaritis, D., and le Roux, C.W. (2021). Do Gut Hormones Contribute to Weight Loss and  
501 Glycaemic Outcomes after Bariatric Surgery? *Nutrients* 13. 10.3390/nu13030762.
- 502 42. Yousseif, A., Emmanuel, J., Karra, E., Millet, Q., Elkalaawy, M., Jenkinson, A.D., Hashemi, M., Adamo,  
503 M., Finer, N., Fiennes, A.G., et al. (2014). Differential effects of laparoscopic sleeve gastrectomy  
504 and laparoscopic gastric bypass on appetite, circulating acyl-ghrelin, peptide YY3-36 and active  
505 GLP-1 levels in non-diabetic humans. *Obes Surg* 24, 241-252. 10.1007/s11695-013-1066-0.
- 506 43. Flint, A., Raben, A., Ersboll, A.K., Holst, J.J., and Astrup, A. (2001). The effect of physiological levels of  
507 glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in  
508 obesity. *International journal of obesity and related metabolic disorders : journal of the*  
509 *International Association for the Study of Obesity* 25, 781-792. 10.1038/sj.ijo.0801627.
- 510

- 511 44. Flint, A., Raben, A., Astrup, A., and Holst, J.J. (1998). Glucagon-like peptide 1 promotes satiety and  
512 suppresses energy intake in humans. *The Journal of clinical investigation* *101*, 515-520.  
513 10.1172/JCI990.
- 514 45. Long, S.J., Sutton, J.A., Amaee, W.B., Giouvanoudi, A., Spyrou, N.M., Rogers, P.J., and Morgan, L.M.  
515 (1999). No effect of glucagon-like peptide-1 on short-term satiety and energy intake in man. *The*  
516 *British journal of nutrition* *81*, 273-279.
- 517 46. Smits, M.M., and Holst, J.J. (2023). Endogenous glucagon-like peptide (GLP)-1 as alternative for GLP-  
518 1 receptor agonists: Could this work and how? *Diabetes Metab Res Rev*, e3699.  
519 10.1002/dmrr.3699.

520